Fact Checked
Fact Checked
This article has been fact checked by a licensed expert before publication to ensure all information provided is correct and safe.
Amycretin
Amycretin is a potential future weight loss drug that's currently in the development stages. It will be similar to popular weight loss drugs like Zepbound and Wegovy, but will contain different active ingredients.
Although there’s limited information on Amycretin and its effectiveness, if it's like the other GLP-1 weight loss injections, it could show promising weight loss results.
Medically reviewed by
Alexandra Cristina Cowell, Writer & Clinical Content Reviewer
Go to
Medically reviewed by
Dr Alexandra Cristina Cowell
Writer & Clinical Content Reviewer
on Mar 20, 2025.
Meet Alexandra Cristina
Last updated on Nov 26, 2025.
Was this article useful?
- Amycretin will be a weight loss treatment in development.
- It will belong to the same category of weight loss drugs as Wegovy and Zepbound.
- It is expected to be available both as an injection and as an oral pill.
What is Amycretin?
Amycretin will be a weight loss treatment and is currently in the early development stages. It will be a dual agonist that targets both GLP-1 receptors—similar to Wegovy and Zepbound—and the amylin receptor. Once approved, it’s expected to be available as an injection and an oral pill.
Amycretin should help increase feelings of fullness and promote satiety, which may help you lose weight. It may also regulate blood sugar levels, though its primary use is likely for weight management rather than diabetes.
How will Amycretin work?
Amycretin is an unimolecular GLP-1 and amylin receptor agonist. These hormones are released after a meal to induce satiety and reduce feelings of hunger, helping you eat less food. Additionally, Amycretin is expected to slow stomach emptying, so you’ll feel fuller for longer.
What doses of Amycretin will there be?
Although details remain limited, the clinical trial data suggest Amycretin pills could be available in 5 different doses: 3 mg, 6 mg, 12 mg, 25 mg, and 50 mg.
The starting dose might be 3 mg, with the maintenance or final dose potentially consisting of two 50 mg doses.
In the early phase of clinical trials, some participants also received 1mg, 1.25mg, 5mg, and 20mg doses, so these could be potential dosage options.
How will Amycretin be administered?
Amycretin is expected to be available as both an injection and an oral pill. The dosage will vary depending on the version you choose.
The oral pill might need to be taken daily, while the injectable treatment might have a weekly dosing schedule, similar to Wegovy.
How long will Amycretin take to work?
There’s limited information on the pharmacokinetic properties of Amycretin, but the clinical trial data found that patients who took a 1.25mg dose lost an average of almost 10% of their body weight by week 20.
Will I get side effects using Amycretin?
Like any medicine, there’s a chance you might get side effects with Amycretin.
While there is no detailed information on the side effects of Amycretin, it’s similar to other GLP-1RAs like Wegovy, so it may share common side effects.
The most common side effects of Wegovy include:
- Headache
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Stomach pain
- Feeling weak.
How effective will Amycretin be?
Early clinical trial data suggest that Amycretin could be an effective weight loss drug. Patients with an average starting weight of 92.7kg lost, after using Amycretin as an injection, approximately:
- 9.7% with a 1.25mg dose by week 20,
- 16.2% with a 5mg dose by week 28, and,
- 22% with a 20mg dose by week 36.
For comparison, patients in the placebo group gained an average of 2% with the 20mg dose.
How will Amycretin compare with other weight loss treatments?
Amycretin is expected to be similar to weight loss drugs like Zepbound, as both are GLP-1 receptor agonists (GLP-1RA). However, there are a few key differences:
- The active ingredient – Amycretin is a GLP-1RA and an amylin RA, whereas Zepbound contains tirzepatide, which is a GLP-1RA and a GIP-RA. This means they’ll work a little differently in the body (although the effect they have should be quite similar).
- The dose – While there are official dosing guidelines for Amycretin, some data suggest that Amycretin pills may be available in 5 doses (3mg, 6mg, 12mg, 25mg and 50mg), whereas Zepbound comes in 6 doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15mg).
- The form – Amycretin is expected to be available as both an injection and an oral pill, whereas Zepbound is only available as an injection.
When will Amycretin be available?
Amycretin is currently in phase 2a of clinical testing, with several phases remaining before it can be approved, including phase 2b and phase 3.
Based on the typical timeline for drug development, it could take around four years for Amycretin to become available to the public.
Reference Popover #ref1
Treated trusted source
Dehestani, B., & Stratford, N. R. (2021).
Amylin as a Future Obesity Treatment. Journal of Obesity & Metabolic Syndrome, 30(4), 320.
Reference Popover #ref2
Treated trusted source
Dehestani, B., & Stratford, N. R. (2021).
ClinicalTrials.gov return to the CTG homepage (2025). A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity. [online] Clinicaltrials.gov.
Reference Popover #ref3
Treated trusted source
Novo Nordisk. (2025).
News Details.
Reference Popover #ref4
Treated trusted source
Novo Nordisk. (2025).
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity.
Reference Popover #ref5
Treated trusted source
Novo Nordisk. (2025).
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity.
Reference Popover #ref6
Treated trusted source
Electronic medicines compendium (2024).
Wegovy - Patient Information Leaflet (PIL) - (emc). [online] Medicines.org.uk.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Tell us what you want to hear.
Have a subject you’d like us to cover in a future article? Let us know.
Give us the inbox treatment.
We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
Find treatment
I'm looking for
Popular searches:
Sign up to our newsletter for all the latest on Weight loss and more.
By clicking 'Subscribe now' you're agreeing to our Privacy Policy.